Shipping to United States We Offer Worldwide Shipping
Login Wishlist

Gomisin S

$610

  • Brand : BIOFRON

  • Catalogue Number : BD-P0504

  • Specification : 98.0%(HPLC)

  • CAS number : 119239-49-5

  • Formula : C23H30O7

  • Molecular Weight : 418.48

  • PUBCHEM ID : 14213995

  • Volume : 5mg

Available on backorder

Quantity
Checkout Bulk Order?

Catalogue Number

BD-P0504

Analysis Method

HPLC,NMR,MS

Specification

98.0%(HPLC)

Storage

-20℃

Molecular Weight

418.48

Appearance

Cryst.

Botanical Source

Structure Type

Lignans

Category

Standards;Natural Pytochemical;API

SMILES

CC1CC2=CC(=C(C(=C2C3=C(C(=C(C=C3C(C1C)O)OC)OC)OC)OC)OC)O

Synonyms

Dibenzo[a,c]cyclooctene-3,8-diol, 5,6,7,8-tetrahydro-1,2,10,11,12-pentamethoxy-6,7-dimethyl-, (6S,7S,8S)-/(6S,7S,8S)-1,2,10,11,12-Pentamethoxy-6,7-dimethyl-5,6,7,8-tetrahydrodibenzo[a,c][8]annulene-3,8-diol

IUPAC Name

(9S,10S,11S)-3,4,14,15,16-pentamethoxy-9,10-dimethyltricyclo[10.4.0.02,7]hexadeca-1(16),2,4,6,12,14-hexaene-5,11-diol

Applications

Density

1.2±0.1 g/cm3

Solubility

Methanol; Ethyl Acetate

Flash Point

313.2±30.1 °C

Boiling Point

594.3±50.0 °C at 760 mmHg

Melting Point

InChl

InChI=1S/C23H30O7/c1-11-8-13-9-15(24)20(27-4)22(29-6)17(13)18-14(19(25)12(11)2)10-16(26-3)21(28-5)23(18)30-7/h9-12,19,24-25H,8H2,1-7H3/t11-,12-,19-/m0/s1

InChl Key

FNANNZAGLCKFOL-ZKTNFTSUSA-N

WGK Germany

RID/ADR

HS Code Reference

2933990000

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:119239-49-5) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.

PMID

29254253

Abstract

Conflicting results identifying the relationship between benzodiazepine drug use and cancer risk. Therefore, we conducted a dose-response meta-analysis of prospective cohort studies to clarify and quantitative assessed the relationship between benzodiazepine drug use and cancer risk. Up to July 2017, 22 original publications were included in current meta-analysis. Our results showed statistically significant association between benzodiazepine drug use and cancer risk (RR:1.25; 95% CI, 1.15-1.36). Subgroup analysis showed benzodiazepine using was associated with significantly a higher risk of breast cancer (RR:1.15; 95% CI, 1.05-1.26), ovarian cancer (RR:1.17; 95% CI, 1.09-1.25), colon cancer (RR:1.07; 95% CI, 1.02-1.13), renal cancer (RR:1.31; 95% CI, 1.15-1.49), malignant melanoma (RR:1.10; 95% CI, 1.03-1.17), brain cancer (RR:2.06; 95% CI, 1.76-2.43), esophagus cancer (RR:1.55; 95% CI, 1.30-1.85), prostate cancer (RR:1.26; 95% CI, 1.16-1.37), liver cancer (RR:1.22; 95% CI, 1.13-1.31), stomach cancer (RR:1.17; 95% CI, 1.03-1.32), pancreatic cancer (RR:1.39; 95% CI, 1.17-1.64) and lung cancer (RR:1.20; 95% CI, 1.12-1.28). Furthermore, a significant dose-response relationship was observed between benzodiazepine drug use and cancer risk (likelihood ratio test, P < 0.001). Our results showed per 500 mg/year, per 5 year of time since first using, per 3 prescriptions and per 3 year of duration incremental increase in benzodiazepine drug use was associated with a 17%, 4%, 16% and 5% in cancer risk increment. Considering these promising results, increasing benzodiazepine using might be harmful for health.

KEYWORDS

cancer, benzodiazepine, dose-response relationship, meta analysis

Title

Benzodiazepine drug use and cancer risk: a dose-response meta analysis of prospective cohort studies

Author

Tao Zhang,#1 Xiaowen Yang,#2 Jianrui Zhou,3 Pei Liu,4 Hui Wang,1 Anrong Li,1 and Yi Zhou1

Publish date

2017 Nov 24

PMID

19239756

Abstract

Southeast Asia will likely be the epicenter of the next influenza pandemic. To determine whether health system resources in Thailand are sufficient to contain an emerging pandemic, we mapped health system resources in 76 provinces. We used 3 prepandemic scenarios of clustered cases and determined resource needs, availability, and gaps. We extended this analysis to a scenario of a modest pandemic and assumed that the same standards of clinical care would be required. We found that gaps exist in many resource categories, even under scenarios in which few cases occur. Such gaps are likely to be profound if a severe pandemic occurs. These gaps exist in infrastructure, personnel and materials, and surveillance capacity. Policy makers must determine whether such resource gaps can realistically be closed, ideally before a pandemic occurs. Alternatively, explicit assumptions must be made regarding allocation of scarce resources, standards of care, and priority setting during a pandemic.

KEYWORDS

Thailand, influenza, pandemic, policy, health system, research

Title

Capacity of Thailand to Contain an Emerging Influenza Pandemic

Author

Weerasak Putthasri, Jongkol Lertiendumrong, Pornthip Chompook, Viroj Tangcharoensathien, and Richard Cokercorresponding author

Publish date

2009 Mar

PMID

19314909

Title

Weekly Reports for DECEMBER 21, 1923

Publish date

1923 Dec 21